Guselkumab, an anti ‐interleukin‐23 monoclonal antibody, for the treatment of moderate to severe plaque‐type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double‐blind, placebo‐controlled study

The Journal of Dermatology, EarlyView.

Source: The Journal of Dermatology - June 15, 2018 Category: Dermatology Authors: Mamitaro Ohtsuki , Hiroshi Kubo , Hitomi Morishima , Ryosuke Goto , Richuan Zheng , Hidemi Nakagawa Source Type: research